Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| 1 |
Industrial Select Sector SPDR Fund
XLI
|
+$236M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$140M |
| 3 |
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
|
+$137M |
| 4 |
VMW
VMware, Inc
VMW
|
+$109M |
| 5 |
iShares MSCI EAFE ETF
EFA
|
+$104M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
+$1.21B |
| 2 |
Apple
AAPL
|
+$779M |
| 3 |
Microsoft
MSFT
|
+$629M |
| 4 |
Consumers Staples Select Sector SPDR Fund
XLP
|
+$601M |
| 5 |
AABA
Altaba Inc. Common Stock
AABA
|
+$384M |
Sector Composition
| 1 | Technology | 15.35% |
| 2 | Healthcare | 12.15% |
| 3 | Financials | 11.41% |
| 4 | Consumer Discretionary | 9.92% |
| 5 | Communication Services | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2751
FerroAtlántica
GSM
$778M
| $164K | ﹤0.01% |
19,078
-4,546
| -19% | -$39.1K |
|
2752
Protagonist Therapeutics
PTGX
$3.65B
| $164K | ﹤0.01% |
24,527
+12,650
| +107% | +$84.6K |
|
2753
iShares Global Energy ETF
IXC
$1.84B
| $163K | ﹤0.01% |
4,367
+630
| +17% | +$23.5K |
|
2754
iShares MSCI Turkey ETF
TUR
$169M
| $163K | ﹤0.01% |
5,397
+119
| +2% | +$3.59K |
|
|
AUTL
2755
Autolus Therapeutics
AUTL
$351M
| $162K | ﹤0.01% |
+6,052
| New | +$162K |
|
|
CRESY
2756
Cresud
CRESY
$523M
| $162K | ﹤0.01% |
12,062
+5,780
| +92% | +$77.6K |
|
2757
Liberty Latin America Class C
LILAK
$1.54B
| $162K | ﹤0.01% |
8,871
+8,322
| +1,516% | +$152K |
|
2758
Ocular Therapeutix
OCUL
$2.19B
| $162K | ﹤0.01% |
24,092
-4,170
| -15% | -$28K |
|
2759
Cenntro
CENN
$28.3M
| $161K | ﹤0.01% |
+2
| New | +$161K |
|
2760
National Vision
EYE
$1.87B
| $161K | ﹤0.01% |
4,406
-5,084
| -54% | -$186K |
|
2761
HNI Corp
HNI
$2.09B
| $161K | ﹤0.01% |
4,338
-10,164
| -70% | -$377K |
|
2762
Kadant
KAI
$3.72B
| $161K | ﹤0.01% |
1,685
-3,019
| -64% | -$288K |
|
2763
MGE Energy Inc
MGEE
$3.11B
| $161K | ﹤0.01% |
2,558
-7,113
| -74% | -$448K |
|
2764
abrdn Physical Gold Shares ETF
SGOL
$5.85B
| $161K | ﹤0.01% |
13,300
| – | – |
|
2765
QuidelOrtho
QDEL
$1.96B
| $160K | ﹤0.01% |
2,401
-8,194
| -77% | -$546K |
|
2766
Rocket Pharmaceuticals
RCKT
$346M
| $160K | ﹤0.01% |
8,156
-27,944
| -77% | -$548K |
|
2767
Evolus
EOLS
$431M
| $159K | ﹤0.01% |
5,708
+4,363
| +324% | +$122K |
|
2768
iShares JPMorgan EM Local Currency Bond ETF
LEMB
$396M
| $159K | ﹤0.01% |
3,585
| – | – |
|
2769
Prudential
PUK
$35.8B
| $159K | ﹤0.01% |
+3,598
| New | +$159K |
|
|
GTHX
2770
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $159K | ﹤0.01% |
3,667
+319
| +10% | +$13.8K |
|
2771
ProShares Short 20+ Year Treasury ETF
TBF
$68.8M
| $158K | ﹤0.01% |
7,000
| – | – |
|
2772
iShares MSCI USA Value Factor ETF
VLUE
$7.28B
| $158K | ﹤0.01% |
1,907
| – | – |
|
|
TRVN
2773
DELISTED
Trevena, Inc.
TRVN
| $158K | ﹤0.01% |
176
+143
| +433% | +$128K |
|
|
FRBK
2774
DELISTED
Republic First Bancorp Inc
FRBK
| $158K | ﹤0.01% |
20,208
+10,058
| +99% | +$78.6K |
|
|
DOVA
2775
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $158K | ﹤0.01% |
5,269
+1,816
| +53% | +$54.5K |
|